Logo Logo

Publications by Verhoef, G.

Up a level
Export as [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date
Number of items: 3.

Journal article

Dreyling, M.; Morschhauser, F.; Bouabdallah, K.; Bron, D.; Cunningham, D.; Assouline, S. E.; Verhoef, G.; Linton, K.; Thieblemont, C.; Vitolo, U.; Hiemeyer, F.; Giurescu, M.; Garcia-Vargas, J.; Gorbatchevsky, I.; Liu, L.; Koechert, K.; Pena, C.; Neves, M.; Childs, B. H.; Zinzani, P. L. (2017): Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. In: Annals of Oncology, Vol. 28, No. 9: pp. 2169-2178

Dreyling, M. H.; Morschhauser, F.; Bouabdallah, K.; Cunningham, D.; Bron, D.; Linton, K.; Assouline, S.; Verhoef, G.; Thieblemont, C.; Vitolo, U.; Garcia-Vargas, J.; Gorbatchevsky, I; Neves, M.; Grunert, J.; Hiemeyer, F.; Childs, B. H.; Zinzani, P. L. (2016): Phase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma. In: Oncology Research and Treatment, Vol. 39: p. 310

Dreyling, M.; Morschhauser, F.; Bouabdallah, K.; Cunningham, D.; Bron, D.; Linton, K.; Assouline, S.; Verhoef, G.; Thieblemont, C.; Vitolo, U.; Garcia-Vargas, J.; Gorbatchevsky, I.; Neves, M.; Grunert, J.; Hiemeyer, F.; Childs, B. H.; Zinzani, P. L. (2016): Phase 2a study of the Phosphatidylinositol-3-Kinase (PI3K) inhibitor Copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma. In: Haematologica, Vol. 101: p. 104

This list was generated on Fri Sep 20 06:38:54 2019 CEST.